<?xml version="1.0" encoding="UTF-8"?>
<abstracts-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:dn="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:ait="http://www.elsevier.com/xml/ani/ait" xmlns:ce="http://www.elsevier.com/xml/ani/common" xmlns:cto="http://www.elsevier.com/xml/cto/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/abstract/scopus_id/85046719054</prism:url><dc:identifier>SCOPUS_ID:85046719054</dc:identifier><eid>2-s2.0-85046719054</eid><pubmed-id>29730448</pubmed-id><pii>S0273230018301272</pii><prism:doi>10.1016/j.yrtph.2018.04.018</prism:doi><dc:title>A big data approach to the concordance of the toxicity of pharmaceuticals in animals and humans</dc:title><prism:aggregationType>Journal</prism:aggregationType><srctype>j</srctype><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><citedby-count>40</citedby-count><prism:publicationName>Regulatory Toxicology and Pharmacology</prism:publicationName><dc:publisher>Academic Press Inc.apjcs@harcourt.com</dc:publisher><source-id>25176</source-id><prism:issn>10960295 02732300</prism:issn><prism:volume>96</prism:volume><prism:startingPage>94</prism:startingPage><prism:endingPage>105</prism:endingPage><prism:pageRange>94-105</prism:pageRange><prism:coverDate>2018-07-01</prism:coverDate><openaccess>1</openaccess><openaccessFlag>true</openaccessFlag><dc:creator><author seq="1" auid="55568513625"><ce:initials>M.</ce:initials><ce:indexed-name>Clark M.</ce:indexed-name><ce:surname>Clark</ce:surname><ce:given-name>Matthew</ce:given-name><preferred-name><ce:initials>M.</ce:initials><ce:indexed-name>Clark M.</ce:indexed-name><ce:surname>Clark</ce:surname><ce:given-name>Matthew</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/55568513625</author-url><affiliation id="60015522" href="https://api.elsevier.com/content/affiliation/affiliation_id/60015522"/></author></dc:creator><dc:description><abstract xmlns="" original="y" xml:lang="eng"><publishercopyright>© 2018 The Author(s)</publishercopyright><ce:para>Although lack of efficacy is an important cause of late stage attrition in drug development the shortcomings in the translation of toxicities observed during the preclinical development to observations in clinical trials or post-approval is an ongoing topic of research. The concordance between preclinical and clinical safety observations has been analyzed only on relatively small data sets, mostly over short time periods of drug approvals. We therefore explored the feasibility of a big-data analysis on a set of 3,290 approved drugs and formulations for which 1,637,449 adverse events were reported for both humans animal species in regulatory submissions over a period of more than 70 years. The events reported in five species – rat, dog, mouse, rabbit, and cynomolgus monkey - were treated as diagnostic tests for human events and the diagnostic power was computed for each event/species pair using likelihood ratios. The animal-human translation of many key observations is confirmed as being predictive, such as QT prolongation and arrhythmias in dog. Our study confirmed the general predictivity of animal safety observations for humans, but also identified issues of such automated analyses which are on the one hand related to data curation and controlled vocabularies, on the other hand to methodological changes over the course of time.</ce:para></abstract></dc:description><link href="https://api.elsevier.com/content/abstract/scopus_id/85046719054" rel="self"/><link href="https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&amp;scp=85046719054&amp;origin=inward" rel="scopus"/><link href="https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&amp;scp=85046719054&amp;origin=inward" rel="scopus-citedby"/></coredata><affiliation id="60015522" href="https://api.elsevier.com/content/affiliation/affiliation_id/60015522"><affilname>Elsevier B.V.</affilname><affiliation-city>Amsterdam</affiliation-city><affiliation-country>Netherlands</affiliation-country></affiliation><affiliation id="60006680" href="https://api.elsevier.com/content/affiliation/affiliation_id/60006680"><affilname>Bayer AG</affilname><affiliation-city>Leverkusen</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><authors><author seq="1" auid="55568513625"><ce:initials>M.</ce:initials><ce:indexed-name>Clark M.</ce:indexed-name><ce:surname>Clark</ce:surname><ce:given-name>Matthew</ce:given-name><preferred-name><ce:initials>M.</ce:initials><ce:indexed-name>Clark M.</ce:indexed-name><ce:surname>Clark</ce:surname><ce:given-name>Matthew</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/55568513625</author-url><affiliation id="60015522" href="https://api.elsevier.com/content/affiliation/affiliation_id/60015522"/></author><author seq="2" auid="6603592872"><ce:initials>T.</ce:initials><ce:indexed-name>Steger-Hartmann T.</ce:indexed-name><ce:surname>Steger-Hartmann</ce:surname><ce:given-name>Thomas</ce:given-name><preferred-name><ce:initials>T.</ce:initials><ce:indexed-name>Steger-Hartmann T.</ce:indexed-name><ce:surname>Steger-Hartmann</ce:surname><ce:given-name>Thomas</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/6603592872</author-url><affiliation id="60006680" href="https://api.elsevier.com/content/affiliation/affiliation_id/60006680"/></author></authors><language xml:lang="eng"/><authkeywords><author-keyword>Adverse event</author-keyword><author-keyword>Big data</author-keyword><author-keyword>Concordance</author-keyword><author-keyword>Predictive value</author-keyword><author-keyword>Predictivity of animal studies</author-keyword><author-keyword>Risk assessment</author-keyword><author-keyword>Signal detection</author-keyword><author-keyword>Translation</author-keyword></authkeywords><idxterms><mainterm weight="b" candidate="n">Animals</mainterm><mainterm weight="a" candidate="n">Big Data</mainterm><mainterm weight="b" candidate="n">Dogs</mainterm><mainterm weight="a" candidate="n">Drug-Related Side Effects and Adverse Reactions</mainterm><mainterm weight="b" candidate="n">Humans</mainterm><mainterm weight="b" candidate="n">Macaca fascicularis</mainterm><mainterm weight="b" candidate="n">Mice</mainterm><mainterm weight="b" candidate="n">Pharmaceutical Preparations</mainterm><mainterm weight="b" candidate="n">Rabbits</mainterm><mainterm weight="b" candidate="n">Rats</mainterm></idxterms><subject-areas><subject-area code="3005" abbrev="PHAR">Toxicology</subject-area></subject-areas><item xmlns=""><xocs:meta><xocs:funding-list has-funding-info="1" pui-match="primary"><xocs:funding-addon-generated-timestamp>2018-05-18T21:47:40.509Z</xocs:funding-addon-generated-timestamp><xocs:funding-addon-type>http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/nlp</xocs:funding-addon-type></xocs:funding-list></xocs:meta><ait:process-info><ait:date-delivered year="2020" month="02" day="10" timestamp="2020-02-10T17:04:20.000020-05:00"/><ait:date-sort year="2018" month="07" day="01"/><ait:status type="core" state="update" stage="S300"/></ait:process-info><bibrecord><item-info><copyright type="Elsevier">Copyright 2018 Elsevier B.V., All rights reserved.</copyright><itemidlist><ce:pii>S0273230018301272</ce:pii><ce:doi>10.1016/j.yrtph.2018.04.018</ce:doi><itemid idtype="PUI">2000745141</itemid><itemid idtype="CABS">2018152029</itemid><itemid idtype="CAR-ID">910633541</itemid><itemid idtype="EMBASE">20180342255</itemid><itemid idtype="EMBIO">2017573651</itemid><itemid idtype="MEDL">29730448</itemid><itemid idtype="REAXYSCAR">20180841912</itemid><itemid idtype="RMC">2018135900</itemid><itemid idtype="SCOPUS">20181549773</itemid><itemid idtype="SCP">85046719054</itemid><itemid idtype="SGR">85046719054</itemid><itemid idtype="PUIsecondary">625499160</itemid></itemidlist><history><date-created year="2018" month="12" day="20" timestamp="BST 08:09:03"/></history><dbcollection>CABS</dbcollection><dbcollection>EMBASE</dbcollection><dbcollection>EMBIO</dbcollection><dbcollection>MEDL</dbcollection><dbcollection>REAXYSCAR</dbcollection><dbcollection>RMC</dbcollection><dbcollection>SCOPUS</dbcollection><dbcollection>Scopusbase</dbcollection><external-source>MEDLINE</external-source></item-info><head><citation-info><citation-type code="ar"/><citation-language xml:lang="eng" language="English"/><abstract-language xml:lang="eng" language="English"/><author-keywords><author-keyword xml:lang="eng">Adverse event</author-keyword><author-keyword xml:lang="eng">Big data</author-keyword><author-keyword xml:lang="eng">Concordance</author-keyword><author-keyword xml:lang="eng">Predictive value</author-keyword><author-keyword xml:lang="eng">Predictivity of animal studies</author-keyword><author-keyword xml:lang="eng">Risk assessment</author-keyword><author-keyword xml:lang="eng">Signal detection</author-keyword><author-keyword xml:lang="eng">Translation</author-keyword></author-keywords></citation-info><citation-title><titletext xml:lang="eng" original="y" language="English">A big data approach to the concordance of the toxicity of pharmaceuticals in animals and humans</titletext></citation-title><author-group><author auid="55568513625" seq="1" type="auth" orcid="0000-0002-5648-6949" date-locked="2018-11-21T04:27:15.446" author-instance-id="S0273230018301272-c30b4d47c391762bcfff566aceb6c4c7"><ce:initials>M.</ce:initials><ce:indexed-name>Clark M.</ce:indexed-name><ce:surname>Clark</ce:surname><ce:given-name>Matthew</ce:given-name><preferred-name><ce:initials>M.</ce:initials><ce:indexed-name>Clark M.</ce:indexed-name><ce:surname>Clark</ce:surname><ce:given-name>Matthew</ce:given-name></preferred-name></author><affiliation afid="60015522" country="usa" affiliation-instance-id="S0273230018301272-dea43b0e045b64867e4cabf5ca24f0f0"><organization>Elsevier R&amp;D Solutions</organization><address-part>1600 JFK Blvd</address-part><city>Philadelphia</city><state>PA</state><postal-code>19103</postal-code><affiliation-id afid="60015522"/><country>United States</country></affiliation></author-group><author-group><author auid="6603592872" seq="2" type="auth" author-instance-id="S0273230018301272-f219eb90c18fcaa86ff9124430714787"><ce:initials>T.</ce:initials><ce:indexed-name>Steger-Hartmann T.</ce:indexed-name><ce:surname>Steger-Hartmann</ce:surname><ce:given-name>Thomas</ce:given-name><preferred-name><ce:initials>T.</ce:initials><ce:indexed-name>Steger-Hartmann T.</ce:indexed-name><ce:surname>Steger-Hartmann</ce:surname><ce:given-name>Thomas</ce:given-name></preferred-name></author><affiliation afid="60006680" dptid="118594223" country="deu" affiliation-instance-id="S0273230018301272-d6e4d4d845c7ebded75ba5cf3837646b"><organization>Investigational Toxicology</organization><organization>Bayer AG</organization><city>Berlin</city><postal-code>13353</postal-code><affiliation-id afid="60006680" dptid="118594223"/><country>Germany</country></affiliation></author-group><correspondence><person><ce:initials>M.</ce:initials><ce:indexed-name>Clark M.</ce:indexed-name><ce:surname>Clark</ce:surname><ce:given-name>Matthew</ce:given-name></person><affiliation country="usa"><organization>Elsevier R&amp;D Solutions</organization><address-part>1600 JFK Blvd</address-part><city>Philadelphia</city><state>PA</state><postal-code>19103</postal-code><country>United States</country></affiliation></correspondence><abstracts><abstract original="y" xml:lang="eng"><publishercopyright>© 2018 The Author(s)</publishercopyright><ce:para>Although lack of efficacy is an important cause of late stage attrition in drug development the shortcomings in the translation of toxicities observed during the preclinical development to observations in clinical trials or post-approval is an ongoing topic of research. The concordance between preclinical and clinical safety observations has been analyzed only on relatively small data sets, mostly over short time periods of drug approvals. We therefore explored the feasibility of a big-data analysis on a set of 3,290 approved drugs and formulations for which 1,637,449 adverse events were reported for both humans animal species in regulatory submissions over a period of more than 70 years. The events reported in five species – rat, dog, mouse, rabbit, and cynomolgus monkey - were treated as diagnostic tests for human events and the diagnostic power was computed for each event/species pair using likelihood ratios. The animal-human translation of many key observations is confirmed as being predictive, such as QT prolongation and arrhythmias in dog. Our study confirmed the general predictivity of animal safety observations for humans, but also identified issues of such automated analyses which are on the one hand related to data curation and controlled vocabularies, on the other hand to methodological changes over the course of time.</ce:para></abstract></abstracts><source srcid="25176" type="j" country="usa"><sourcetitle>Regulatory Toxicology and Pharmacology</sourcetitle><sourcetitle-abbrev>Regul. Toxicol. Pharmacol.</sourcetitle-abbrev><translated-sourcetitle xml:lang="eng">Regulatory Toxicology and Pharmacology</translated-sourcetitle><issn type="electronic">10960295</issn><issn type="print">02732300</issn><codencode>RTOPD</codencode><volisspag><voliss volume="96"/><pagerange first="94" last="105"/></volisspag><publicationyear first="2018"/><publicationdate><year>2018</year><month>07</month><day>01</day><date-text>July 2018</date-text></publicationdate><website><ce:e-address type="email">http://www.elsevier.com/inca/publications/store/6/2/2/9/3/9/index.htt</ce:e-address></website><publisher><publishername>Academic Press Inc.</publishername><ce:e-address type="email">apjcs@harcourt.com</ce:e-address></publisher></source><enhancement><classificationgroup><classifications type="CABSCLASS"><classification>                                 <classification-code>90.4.2</classification-code>                                 <classification-description>TOXICOLOGY; CLINICAL TOXICOLOGY (by agent); Drugs and Pharmaceuticals</classification-description>                             </classification><classification>                                 <classification-code>90.5.2</classification-code>                                 <classification-description>TOXICOLOGY; EXPERIMENTAL TOXICOLOGY (by agent); Drugs and Pharmaceuticals</classification-description>                             </classification></classifications><classifications type="EMCLASS"><classification>                                 <classification-code>37</classification-code>                                 <classification-description>Drug Literature Index</classification-description>                             </classification><classification>                                 <classification-code>52</classification-code>                                 <classification-description>Toxicology</classification-description>                             </classification></classifications><classifications type="ASJC"><classification>3005</classification></classifications><classifications type="SUBJABBR"><classification>PHAR</classification></classifications></classificationgroup><chemicalgroup><chemicals source="esbd"><chemical><chemical-name>oxycodone</chemical-name><cas-registry-number>124-90-3</cas-registry-number><cas-registry-number>76-42-6</cas-registry-number></chemical></chemicals><chemicals source="nlm"><chemical><chemical-name>Pharmaceutical Preparations</chemical-name></chemical></chemicals></chemicalgroup></enhancement></head><tail><bibliography refcount="31"><reference id="1"><ref-info><refd-itemidlist><itemid idtype="DOI">10.4135/9781446218525</itemid><itemid idtype="FRAGMENTID">bib1</itemid><itemid idtype="SGR">0003479379</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>D.G.</ce:initials><ce:indexed-name>Altman D.G.</ce:indexed-name><ce:surname>Altman</ce:surname></author><author seq="2"><ce:initials>D.</ce:initials><ce:indexed-name>Machin D.</ce:indexed-name><ce:surname>Machin</ce:surname></author><author seq="3"><ce:initials>T.N.</ce:initials><ce:indexed-name>Bryant T.N.</ce:indexed-name><ce:surname>Bryant</ce:surname></author><author seq="4"><ce:initials>M.J.</ce:initials><ce:indexed-name>Gardner M.J.</ce:indexed-name><ce:surname>Gardner</ce:surname></author></ref-authors><ref-sourcetitle>Statistics with Confidence</ref-sourcetitle><ref-publicationyear first="2000"/><ref-volisspag><voliss volume="252"/></ref-volisspag><ref-text>BMJ Books</ref-text></ref-info><ref-fulltext>Altman, D.G., Machin, D., Bryant, T.N., Gardner, M.J., Statistics with Confidence, vol. 252, 2000, BMJ Books, 10.4135/9781446218525.</ref-fulltext></reference><reference id="2"><ref-info><ref-title><ref-titletext>Systematic reviews of animal experiments demonstrate poor human clinical and toxicological utility</ref-titletext></ref-title><refd-itemidlist><itemid idtype="FRAGMENTID">bib2</itemid><itemid idtype="SGR">85046707789</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:indexed-name>Andrew Knight</ce:indexed-name><ce:surname>Andrew Knight</ce:surname></author></ref-authors><ref-sourcetitle>Altern. to Lab. Anim</ref-sourcetitle><ref-publicationyear first="2007"/><ref-volisspag><voliss volume="36"/></ref-volisspag></ref-info><ref-fulltext>Andrew Knight, Systematic reviews of animal experiments demonstrate poor human clinical and toxicological utility. Altern. to Lab. Anim, 36, 2007.</ref-fulltext></reference><reference id="3"><ref-info><ref-title><ref-titletext>An analysis of the use of animal models in predicting human toxicology and drug safety</ref-titletext></ref-title><refd-itemidlist><itemid idtype="FRAGMENTID">bib3</itemid><itemid idtype="SGR">84907424934</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>J.</ce:initials><ce:indexed-name>Bailey J.</ce:indexed-name><ce:surname>Bailey</ce:surname></author><author seq="2"><ce:initials>M.</ce:initials><ce:indexed-name>Thew M.</ce:indexed-name><ce:surname>Thew</ce:surname></author><author seq="3"><ce:initials>M.</ce:initials><ce:indexed-name>Balls M.</ce:indexed-name><ce:surname>Balls</ce:surname></author></ref-authors><ref-sourcetitle>Altern. to Lab. Anim</ref-sourcetitle><ref-publicationyear first="2014"/><ref-volisspag><voliss volume="42"/><pagerange first="181" last="199"/></ref-volisspag></ref-info><ref-fulltext>Bailey, J., Thew, M., Balls, M., An analysis of the use of animal models in predicting human toxicology and drug safety. Altern. to Lab. Anim 42 (2014), 181–199.</ref-fulltext></reference><reference id="4"><ref-info><ref-title><ref-titletext>Nonhuman primates: laboratory animals of choice for neurophysiologic studies of sleep</ref-titletext></ref-title><refd-itemidlist><itemid idtype="FRAGMENTID">bib4</itemid><itemid idtype="SGR">0017566484</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>E.</ce:initials><ce:indexed-name>Balzamo E.</ce:indexed-name><ce:surname>Balzamo</ce:surname></author><author seq="2"><ce:initials>V.</ce:initials><ce:indexed-name>Santucci V.</ce:indexed-name><ce:surname>Santucci</ce:surname></author><author seq="3"><ce:initials>B.</ce:initials><ce:indexed-name>Seri B.</ce:indexed-name><ce:surname>Seri</ce:surname></author><author seq="4"><ce:initials>G.</ce:initials><ce:indexed-name>Vuillon-Cacciuttolo G.</ce:indexed-name><ce:surname>Vuillon-Cacciuttolo</ce:surname></author><author seq="5"><ce:initials>J.</ce:initials><ce:indexed-name>Bert J.</ce:indexed-name><ce:surname>Bert</ce:surname></author></ref-authors><ref-sourcetitle>Lab. Anim. Sci.</ref-sourcetitle><ref-publicationyear first="1977"/><ref-volisspag><voliss volume="27"/><pagerange first="879" last="886"/></ref-volisspag></ref-info><ref-fulltext>Balzamo, E., Santucci, V., Seri, B., Vuillon-Cacciuttolo, G., Bert, J., Nonhuman primates: laboratory animals of choice for neurophysiologic studies of sleep. Lab. Anim. Sci. 27 (1977), 879–886.</ref-fulltext></reference><reference id="5"><ref-info><ref-title><ref-titletext>The medical dictionary for regulatory activities (MedDRA)</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.2165/00002018-199920020-00002</itemid><itemid idtype="FRAGMENTID">bib5</itemid><itemid idtype="SGR">0032991290</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>E.G.</ce:initials><ce:indexed-name>Brown E.G.</ce:indexed-name><ce:surname>Brown</ce:surname></author><author seq="2"><ce:initials>L.</ce:initials><ce:indexed-name>Wood L.</ce:indexed-name><ce:surname>Wood</ce:surname></author><author seq="3"><ce:initials>S.</ce:initials><ce:indexed-name>Wood S.</ce:indexed-name><ce:surname>Wood</ce:surname></author></ref-authors><ref-sourcetitle>Drug Saf.</ref-sourcetitle><ref-publicationyear first="1999"/></ref-info><ref-fulltext>Brown, E.G., Wood, L., Wood, S., The medical dictionary for regulatory activities (MedDRA). Drug Saf., 1999, 10.2165/00002018-199920020-00002.</ref-fulltext></reference><reference id="6"><ref-info><ref-title><ref-titletext>Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets</ref-titletext></ref-title><refd-itemidlist><itemid idtype="FRAGMENTID">bib6</itemid><itemid idtype="SGR">84860854354</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>P.J.</ce:initials><ce:indexed-name>Bugelski P.J.</ce:indexed-name><ce:surname>Bugelski</ce:surname></author><author seq="2"><ce:initials>P.L.</ce:initials><ce:indexed-name>Martin P.L.</ce:indexed-name><ce:surname>Martin</ce:surname></author></ref-authors><ref-sourcetitle>Br. J. Pharmacol.</ref-sourcetitle><ref-publicationyear first="2012"/><ref-volisspag><voliss volume="166" issue="3"/><pagerange first="823" last="846"/></ref-volisspag></ref-info><ref-fulltext>Bugelski, P.J., Martin, P.L., Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets. Br. J. Pharmacol. 166:3 (2012), 823–846.</ref-fulltext></reference><reference id="7"><ref-info><ref-title><ref-titletext>Species selection considerations for preclinical toxicology studies for biotherapeutics</ref-titletext></ref-title><refd-itemidlist><itemid idtype="FRAGMENTID">bib7</itemid><itemid idtype="SGR">49649101856</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>J.L.</ce:initials><ce:indexed-name>Bussiere J.L.</ce:indexed-name><ce:surname>Bussiere</ce:surname></author></ref-authors><ref-sourcetitle>Expet Opin. Drug Metabol. Toxicol.</ref-sourcetitle><ref-publicationyear first="2008"/><ref-volisspag><voliss volume="4" issue="7"/><pagerange first="871" last="877"/></ref-volisspag></ref-info><ref-fulltext>Bussiere, J.L., Species selection considerations for preclinical toxicology studies for biotherapeutics. Expet Opin. Drug Metabol. Toxicol. 4:7 (2008), 871–877.</ref-fulltext></reference><reference id="8"><ref-info><ref-title><ref-titletext>Evaluation of a clinical test. II: assessment of validity</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.1016/S0306-5456(00)00128-5</itemid><itemid idtype="FRAGMENTID">bib8</itemid><itemid idtype="SGR">0035380779</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>P.F.W.</ce:initials><ce:indexed-name>Chien P.F.W.</ce:indexed-name><ce:surname>Chien</ce:surname></author><author seq="2"><ce:initials>K.S.</ce:initials><ce:indexed-name>Khan K.S.</ce:indexed-name><ce:surname>Khan</ce:surname></author></ref-authors><ref-sourcetitle>Br. J. Obstet. Gynaecol.</ref-sourcetitle><ref-publicationyear first="2001"/><ref-volisspag><voliss volume="108"/><pagerange first="568" last="572"/></ref-volisspag></ref-info><ref-fulltext>Chien, P.F.W., Khan, K.S., Evaluation of a clinical test. II: assessment of validity. Br. J. Obstet. Gynaecol. 108 (2001), 568–572, 10.1016/S0306-5456(00)00128-5.</ref-fulltext></reference><reference id="9"><ref-info><ref-title><ref-titletext>Prediction of clinical risks by analysis of preclinical and clinical adverse events</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.1016/j.jbi.2015.02.008</itemid><itemid idtype="FRAGMENTID">bib9</itemid><itemid idtype="SGR">84927927473</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>M.</ce:initials><ce:indexed-name>Clark M.</ce:indexed-name><ce:surname>Clark</ce:surname></author></ref-authors><ref-sourcetitle>J. Biomed. Inf.</ref-sourcetitle><ref-publicationyear first="2015"/><ref-volisspag><voliss volume="54"/><pagerange first="167" last="173"/></ref-volisspag></ref-info><ref-fulltext>Clark, M., Prediction of clinical risks by analysis of preclinical and clinical adverse events. J. Biomed. Inf. 54 (2015), 167–173, 10.1016/j.jbi.2015.02.008.</ref-fulltext></reference><reference id="10"><ref-info><ref-title><ref-titletext>Pharmacology Review 205436/S-000 Part 02 Tedizolid</ref-titletext></ref-title><refd-itemidlist><itemid idtype="FRAGMENTID">bib10</itemid><itemid idtype="SGR">85046718263</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:indexed-name>Cubist Pharmaceuticals</ce:indexed-name><ce:surname>Cubist Pharmaceuticals</ce:surname></author></ref-authors><ref-publicationyear first="2013"/></ref-info><ref-fulltext>Cubist Pharmaceuticals, Pharmacology Review 205436/S-000 Part 02 Tedizolid. 2013.</ref-fulltext></reference><reference id="11"><ref-info><ref-title><ref-titletext>Meyler's Side Effects of Drugs</ref-titletext></ref-title><refd-itemidlist><itemid idtype="FRAGMENTID">bib11</itemid><itemid idtype="SGR">0003845352</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>M.N.G.</ce:initials><ce:indexed-name>Dukes M.N.G.</ce:indexed-name><ce:surname>Dukes</ce:surname></author></ref-authors><ref-publicationyear first="1992"/><ref-text>twelfth ed. Elsevier Science Publishers BV Amsterdam, Amsterdam</ref-text></ref-info><ref-fulltext>Dukes, M.N.G., Meyler's Side Effects of Drugs. twelfth ed., 1992, Elsevier Science Publishers BV, Amsterdam, Amsterdam.</ref-fulltext></reference><reference id="12"><ref-info><ref-title><ref-titletext>Pharmacology Review 021611/S-000; 021610/S-000 Part 04 Oxycodone Hydrochloride</ref-titletext></ref-title><refd-itemidlist><itemid idtype="FRAGMENTID">bib12</itemid><itemid idtype="SGR">85046817429</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:indexed-name>Endo Pharmaceuticals</ce:indexed-name><ce:surname>Endo Pharmaceuticals</ce:surname></author></ref-authors><ref-publicationyear first="2011"/></ref-info><ref-fulltext>Endo Pharmaceuticals, Pharmacology Review 021611/S-000; 021610/S-000 Part 04 Oxycodone Hydrochloride. 2011.</ref-fulltext></reference><reference id="13"><ref-info><ref-title><ref-titletext>The concordance between nonclinical and phase I clinical cardiovascular assessment from a cross-company data sharing initiative</ref-titletext></ref-title><refd-itemidlist><itemid idtype="FRAGMENTID">bib13</itemid><itemid idtype="SGR">84921737927</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>L.</ce:initials><ce:indexed-name>Ewart L.</ce:indexed-name><ce:surname>Ewart</ce:surname></author><author seq="2"><ce:initials>M.</ce:initials><ce:indexed-name>Aylott M.</ce:indexed-name><ce:surname>Aylott</ce:surname></author><author seq="3"><ce:initials>M.</ce:initials><ce:indexed-name>Deurinck M.</ce:indexed-name><ce:surname>Deurinck</ce:surname></author><author seq="4"><ce:initials>M.</ce:initials><ce:indexed-name>Engwall M.</ce:indexed-name><ce:surname>Engwall</ce:surname></author><author seq="5"><ce:initials>D.J.</ce:initials><ce:indexed-name>Gallacher D.J.</ce:indexed-name><ce:surname>Gallacher</ce:surname></author><author seq="6"><ce:initials>H.</ce:initials><ce:indexed-name>Geys H.</ce:indexed-name><ce:surname>Geys</ce:surname></author><author seq="7"><ce:initials>P.</ce:initials><ce:indexed-name>Jarvis P.</ce:indexed-name><ce:surname>Jarvis</ce:surname></author><author seq="8"><ce:initials>H.</ce:initials><ce:indexed-name>Ju H.</ce:indexed-name><ce:surname>Ju</ce:surname></author><author seq="9"><ce:initials>D.</ce:initials><ce:indexed-name>Leishman D.</ce:indexed-name><ce:surname>Leishman</ce:surname></author><author seq="10"><ce:initials>L.</ce:initials><ce:indexed-name>Leong L.</ce:indexed-name><ce:surname>Leong</ce:surname></author><author seq="11"><ce:initials>N.</ce:initials><ce:indexed-name>McMahon N.</ce:indexed-name><ce:surname>McMahon</ce:surname></author><author seq="12"><ce:initials>A.</ce:initials><ce:indexed-name>Mead A.</ce:indexed-name><ce:surname>Mead</ce:surname></author><author seq="13"><ce:initials>P.</ce:initials><ce:indexed-name>Milliken P.</ce:indexed-name><ce:surname>Milliken</ce:surname></author><author seq="14"><ce:initials>W.</ce:initials><ce:indexed-name>Suter W.</ce:indexed-name><ce:surname>Suter</ce:surname></author><author seq="15"><ce:initials>A.</ce:initials><ce:indexed-name>Teisman A.</ce:indexed-name><ce:surname>Teisman</ce:surname></author><author seq="16"><ce:initials>K.</ce:initials><ce:indexed-name>Van Ammel K.</ce:indexed-name><ce:surname>Van Ammel</ce:surname></author><author seq="17"><ce:initials>H.M.</ce:initials><ce:indexed-name>Vargas H.M.</ce:indexed-name><ce:surname>Vargas</ce:surname></author><author seq="18"><ce:initials>R.</ce:initials><ce:indexed-name>Wallis R.</ce:indexed-name><ce:surname>Wallis</ce:surname></author><author seq="19"><ce:initials>J.P.</ce:initials><ce:indexed-name>Valentin J.P.</ce:indexed-name><ce:surname>Valentin</ce:surname></author></ref-authors><ref-sourcetitle>Toxicol. Sci.</ref-sourcetitle><ref-publicationyear first="2014"/><ref-volisspag><voliss volume="142" issue="2"/><pagerange first="427" last="435"/></ref-volisspag></ref-info><ref-fulltext>Ewart, L., Aylott, M., Deurinck, M., Engwall, M., Gallacher, D.J., Geys, H., Jarvis, P., Ju, H., Leishman, D., Leong, L., McMahon, N., Mead, A., Milliken, P., Suter, W., Teisman, A., Van Ammel, K., Vargas, H.M., Wallis, R., Valentin, J.P., The concordance between nonclinical and phase I clinical cardiovascular assessment from a cross-company data sharing initiative. Toxicol. Sci. 142:2 (2014), 427–435.</ref-fulltext></reference><reference id="14"><ref-info><ref-title><ref-titletext>Drug safety tests and subsequent clinical experience</ref-titletext></ref-title><refd-itemidlist><itemid idtype="FRAGMENTID">bib14</itemid><itemid idtype="SGR">0018013604</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>A.P.</ce:initials><ce:indexed-name>Fletcher A.P.</ce:indexed-name><ce:surname>Fletcher</ce:surname></author></ref-authors><ref-sourcetitle>J. R. Soc. Med.</ref-sourcetitle><ref-publicationyear first="1978"/><ref-volisspag><voliss volume="71"/><pagerange first="693" last="696"/></ref-volisspag></ref-info><ref-fulltext>Fletcher, A.P., Drug safety tests and subsequent clinical experience. J. R. Soc. Med. 71 (1978), 693–696.</ref-fulltext></reference><reference id="15"><ref-info><ref-title><ref-titletext>First dose of potential new medicines to humans: how animals help</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.1038/nrd1329</itemid><itemid idtype="FRAGMENTID">bib15</itemid><itemid idtype="SGR">1642282158</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>P.</ce:initials><ce:indexed-name>Greaves P.</ce:indexed-name><ce:surname>Greaves</ce:surname></author><author seq="2"><ce:initials>A.</ce:initials><ce:indexed-name>Williams A.</ce:indexed-name><ce:surname>Williams</ce:surname></author><author seq="3"><ce:initials>M.</ce:initials><ce:indexed-name>Eve M.</ce:indexed-name><ce:surname>Eve</ce:surname></author></ref-authors><ref-sourcetitle>Nat. Rev. Drug Discov.</ref-sourcetitle><ref-publicationyear first="2004"/><ref-volisspag><voliss volume="3"/><pagerange first="226" last="236"/></ref-volisspag></ref-info><ref-fulltext>Greaves, P., Williams, A., Eve, M., First dose of potential new medicines to humans: how animals help. Nat. Rev. Drug Discov. 3 (2004), 226–236, 10.1038/nrd1329.</ref-fulltext></reference><reference id="16"><ref-info><ref-title><ref-titletext>Refining clinical diagnosis with likelihood ratios</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.1016/S0140-6736(05)66422-7</itemid><itemid idtype="FRAGMENTID">bib16</itemid><itemid idtype="SGR">17844402965</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>D.A.</ce:initials><ce:indexed-name>Grimes D.A.</ce:indexed-name><ce:surname>Grimes</ce:surname></author><author seq="2"><ce:initials>K.F.</ce:initials><ce:indexed-name>Schulz K.F.</ce:indexed-name><ce:surname>Schulz</ce:surname></author></ref-authors><ref-sourcetitle>Lancet</ref-sourcetitle><ref-publicationyear first="2005"/><ref-volisspag><voliss volume="365"/><pagerange first="1500" last="1505"/></ref-volisspag></ref-info><ref-fulltext>Grimes, D.A., Schulz, K.F., Refining clinical diagnosis with likelihood ratios. Lancet 365 (2005), 1500–1505, 10.1016/S0140-6736(05)66422-7.</ref-fulltext></reference><reference id="17"><ref-info><ref-title><ref-titletext>Simplifying likelihood ratios</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.1046/j.1525-1497.2002.10750.x</itemid><itemid idtype="FRAGMENTID">bib17</itemid><itemid idtype="SGR">0036042766</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>S.</ce:initials><ce:indexed-name>McGee S.</ce:indexed-name><ce:surname>McGee</ce:surname></author></ref-authors><ref-sourcetitle>J. Gen. Intern. Med.</ref-sourcetitle><ref-publicationyear first="2002"/><ref-volisspag><voliss volume="17"/><pagerange first="647" last="650"/></ref-volisspag></ref-info><ref-fulltext>McGee, S., Simplifying likelihood ratios. J. Gen. Intern. Med. 17 (2002), 647–650, 10.1046/j.1525-1497.2002.10750.x.</ref-fulltext></reference><reference id="18"><ref-info><ref-title><ref-titletext>Assessing the predictive value of the rodent neurofunctional assessment for commonly reported adverse events in phase I clinical trials</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.1016/j.yrtph.2016.05.002</itemid><itemid idtype="FRAGMENTID">bib18</itemid><itemid idtype="SGR">84973557282</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>A.N.</ce:initials><ce:indexed-name>Mead A.N.</ce:indexed-name><ce:surname>Mead</ce:surname></author><author seq="2"><ce:initials>H.R.</ce:initials><ce:indexed-name>Amouzadeh H.R.</ce:indexed-name><ce:surname>Amouzadeh</ce:surname></author><author seq="3"><ce:initials>K.</ce:initials><ce:indexed-name>Chapman K.</ce:indexed-name><ce:surname>Chapman</ce:surname></author><author seq="4"><ce:initials>L.</ce:initials><ce:indexed-name>Ewart L.</ce:indexed-name><ce:surname>Ewart</ce:surname></author><author seq="5"><ce:initials>A.</ce:initials><ce:indexed-name>Giarola A.</ce:indexed-name><ce:surname>Giarola</ce:surname></author><author seq="6"><ce:initials>S.J.</ce:initials><ce:indexed-name>Jackson S.J.</ce:indexed-name><ce:surname>Jackson</ce:surname></author><author seq="7"><ce:initials>P.</ce:initials><ce:indexed-name>Jarvis P.</ce:indexed-name><ce:surname>Jarvis</ce:surname></author><author seq="8"><ce:initials>P.</ce:initials><ce:indexed-name>Jordaan P.</ce:indexed-name><ce:surname>Jordaan</ce:surname></author><author seq="9"><ce:initials>W.</ce:initials><ce:indexed-name>Redfern W.</ce:indexed-name><ce:surname>Redfern</ce:surname></author><author seq="10"><ce:initials>M.</ce:initials><ce:indexed-name>Traebert M.</ce:indexed-name><ce:surname>Traebert</ce:surname></author><author seq="11"><ce:initials>J.P.</ce:initials><ce:indexed-name>Valentin J.P.</ce:indexed-name><ce:surname>Valentin</ce:surname></author><author seq="12"><ce:initials>H.M.</ce:initials><ce:indexed-name>Vargas H.M.</ce:indexed-name><ce:surname>Vargas</ce:surname></author></ref-authors><ref-sourcetitle>Regul. Toxicol. Pharmacol.</ref-sourcetitle><ref-publicationyear first="2016"/><ref-volisspag><voliss volume="80"/><pagerange first="348" last="357"/></ref-volisspag></ref-info><ref-fulltext>Mead, A.N., Amouzadeh, H.R., Chapman, K., Ewart, L., Giarola, A., Jackson, S.J., Jarvis, P., Jordaan, P., Redfern, W., Traebert, M., Valentin, J.P., Vargas, H.M., Assessing the predictive value of the rodent neurofunctional assessment for commonly reported adverse events in phase I clinical trials. Regul. Toxicol. Pharmacol. 80 (2016), 348–357, 10.1016/j.yrtph.2016.05.002.</ref-fulltext></reference><reference id="19"><ref-info><ref-title><ref-titletext>Drug development and nonclinical to clinical translational databases</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.1177/0192623314557189</itemid><itemid idtype="FRAGMENTID">bib19</itemid><itemid idtype="SGR">84921758463</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>T.M.</ce:initials><ce:indexed-name>Monticello T.M.</ce:indexed-name><ce:surname>Monticello</ce:surname></author></ref-authors><ref-sourcetitle>Toxicol. Pathol.</ref-sourcetitle><ref-publicationyear first="2015"/><ref-volisspag><voliss volume="43"/><pagerange first="57" last="61"/></ref-volisspag></ref-info><ref-fulltext>Monticello, T.M., Drug development and nonclinical to clinical translational databases. Toxicol. Pathol. 43 (2015), 57–61, 10.1177/0192623314557189.</ref-fulltext></reference><reference id="20"><ref-info><ref-title><ref-titletext>Current nonclinical testing paradigm enables safe entry to First-In-Human clinical trials: the IQ consortium nonclinical to clinical translational database</ref-titletext></ref-title><refd-itemidlist><itemid idtype="FRAGMENTID">bib20</itemid><itemid idtype="SGR">85029393256</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>T.M.</ce:initials><ce:indexed-name>Monticello T.M.</ce:indexed-name><ce:surname>Monticello</ce:surname></author><author seq="2"><ce:initials>T.W.</ce:initials><ce:indexed-name>Jones T.W.</ce:indexed-name><ce:surname>Jones</ce:surname></author><author seq="3"><ce:initials>D.M.</ce:initials><ce:indexed-name>Dambach D.M.</ce:indexed-name><ce:surname>Dambach</ce:surname></author><author seq="4"><ce:initials>D.M.</ce:initials><ce:indexed-name>Potter D.M.</ce:indexed-name><ce:surname>Potter</ce:surname></author><author seq="5"><ce:initials>M.W.</ce:initials><ce:indexed-name>Bolte M.W.</ce:indexed-name><ce:surname>Bolte</ce:surname></author><author seq="6"><ce:initials>M.</ce:initials><ce:indexed-name>Liuf M.</ce:indexed-name><ce:surname>Liuf</ce:surname></author><author seq="7"><ce:initials>D.A.</ce:initials><ce:indexed-name>Keller D.A.</ce:indexed-name><ce:surname>Keller</ce:surname></author><author seq="8"><ce:initials>T.K.</ce:initials><ce:indexed-name>Harth T.K.</ce:indexed-name><ce:surname>Harth</ce:surname></author><author seq="9"><ce:initials>V.J.</ce:initials><ce:indexed-name>Kadambi V.J.</ce:indexed-name><ce:surname>Kadambi</ce:surname></author></ref-authors><ref-sourcetitle>Toxicol. Appl. Pharmacol.</ref-sourcetitle><ref-publicationyear first="2017"/><ref-volisspag><voliss volume="334"/><pagerange first="100" last="109"/></ref-volisspag></ref-info><ref-fulltext>Monticello, T.M., Jones, T.W., Dambach, D.M., Potter, D.M., Bolte, M.W., Liuf, M., Keller, D.A., Harth, T.K., Kadambi, V.J., Current nonclinical testing paradigm enables safe entry to First-In-Human clinical trials: the IQ consortium nonclinical to clinical translational database. Toxicol. Appl. Pharmacol. 334 (2017), 100–109.</ref-fulltext></reference><reference id="21"><ref-info><refd-itemidlist><itemid idtype="FRAGMENTID">bib21</itemid><itemid idtype="SGR">0004122190</itemid></refd-itemidlist><ref-sourcetitle>Mosby's Drug Consult 13th Edition</ref-sourcetitle><ref-publicationyear first="2003"/><ref-text>(Mosby, St. Louis, MO)</ref-text></ref-info><ref-fulltext>Mosby's Drug Consult 13th Edition, 2003 (Mosby, St. Louis, MO).</ref-fulltext></reference><reference id="22"><ref-info><ref-title><ref-titletext>Concordance of the toxicity of pharmaceuticals in humans and in animals</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.1006/rtph.2000.1399</itemid><itemid idtype="FRAGMENTID">bib22</itemid><itemid idtype="SGR">0033771951</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>H.</ce:initials><ce:indexed-name>Olson H.</ce:indexed-name><ce:surname>Olson</ce:surname></author><author seq="2"><ce:initials>G.</ce:initials><ce:indexed-name>Betton G.</ce:indexed-name><ce:surname>Betton</ce:surname></author><author seq="3"><ce:initials>D.</ce:initials><ce:indexed-name>Robinson D.</ce:indexed-name><ce:surname>Robinson</ce:surname></author><author seq="4"><ce:initials>K.</ce:initials><ce:indexed-name>Thomas K.</ce:indexed-name><ce:surname>Thomas</ce:surname></author><author seq="5"><ce:initials>A.</ce:initials><ce:indexed-name>Monro A.</ce:indexed-name><ce:surname>Monro</ce:surname></author><author seq="6"><ce:initials>G.</ce:initials><ce:indexed-name>Kolaja G.</ce:indexed-name><ce:surname>Kolaja</ce:surname></author><author seq="7"><ce:initials>P.</ce:initials><ce:indexed-name>Lilly P.</ce:indexed-name><ce:surname>Lilly</ce:surname></author><author seq="8"><ce:initials>J.</ce:initials><ce:indexed-name>Sanders J.</ce:indexed-name><ce:surname>Sanders</ce:surname></author><author seq="9"><ce:initials>G.</ce:initials><ce:indexed-name>Sipes G.</ce:indexed-name><ce:surname>Sipes</ce:surname></author><author seq="10"><ce:initials>W.</ce:initials><ce:indexed-name>Bracken W.</ce:indexed-name><ce:surname>Bracken</ce:surname></author><author seq="11"><ce:initials>M.</ce:initials><ce:indexed-name>Dorato M.</ce:indexed-name><ce:surname>Dorato</ce:surname></author><author seq="12"><ce:initials>K.</ce:initials><ce:indexed-name>Van Deun K.</ce:indexed-name><ce:surname>Van Deun</ce:surname></author><author seq="13"><ce:initials>P.</ce:initials><ce:indexed-name>Smith P.</ce:indexed-name><ce:surname>Smith</ce:surname></author><author seq="14"><ce:initials>B.</ce:initials><ce:indexed-name>Berger B.</ce:indexed-name><ce:surname>Berger</ce:surname></author><author seq="15"><ce:initials>A.</ce:initials><ce:indexed-name>Heller A.</ce:indexed-name><ce:surname>Heller</ce:surname></author></ref-authors><ref-sourcetitle>Regul. Toxicol. Pharmacol.</ref-sourcetitle><ref-publicationyear first="2000"/><ref-volisspag><voliss volume="32"/><pagerange first="56" last="67"/></ref-volisspag></ref-info><ref-fulltext>Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., Dorato, M., Van Deun, K., Smith, P., Berger, B., Heller, A., Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 32 (2000), 56–67, 10.1006/rtph.2000.1399.</ref-fulltext></reference><reference id="23"><ref-info><refd-itemidlist><itemid idtype="FRAGMENTID">bib23</itemid><itemid idtype="SGR">85046826488</itemid></refd-itemidlist><ref-sourcetitle>PharmaPendium Reed Elsevier Properties SA [WWW Document]</ref-sourcetitle><ref-publicationyear first="2014"/><ref-website><ce:e-address type="email">https://pharmapendium.com</ce:e-address></ref-website></ref-info><ref-fulltext>PharmaPendium Reed Elsevier Properties SA [WWW Document], 2014 https://pharmapendium.com.</ref-fulltext></reference><reference id="24"><ref-info><ref-title><ref-titletext>Are animal models predictive for humans?</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.1186/1747-5341-4-2</itemid><itemid idtype="FRAGMENTID">bib24</itemid><itemid idtype="SGR">60949086792</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>N.</ce:initials><ce:indexed-name>Shanks N.</ce:indexed-name><ce:surname>Shanks</ce:surname></author><author seq="2"><ce:initials>R.</ce:initials><ce:indexed-name>Greek R.</ce:indexed-name><ce:surname>Greek</ce:surname></author><author seq="3"><ce:initials>J.</ce:initials><ce:indexed-name>Greek J.</ce:indexed-name><ce:surname>Greek</ce:surname></author></ref-authors><ref-sourcetitle>Philos. Ethics Humanit. Med.</ref-sourcetitle><ref-publicationyear first="2009"/><ref-volisspag><voliss volume="4"/><pagerange first="2"/></ref-volisspag></ref-info><ref-fulltext>Shanks, N., Greek, R., Greek, J., Are animal models predictive for humans?. Philos. Ethics Humanit. Med., 4, 2009, 2, 10.1186/1747-5341-4-2.</ref-fulltext></reference><reference id="25"><ref-info><ref-title><ref-titletext>Potentials and limitations of nonclinical safety assessment for predicting clinical adverse drug reactions: correlation analysis of 142 approved drugs in Japan</ref-titletext></ref-title><refd-itemidlist><itemid idtype="FRAGMENTID">bib25</itemid><itemid idtype="SGR">84879682740</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>C.</ce:initials><ce:indexed-name>Tamaki C.</ce:indexed-name><ce:surname>Tamaki</ce:surname></author><author seq="2"><ce:initials>T.</ce:initials><ce:indexed-name>Nagayama T.</ce:indexed-name><ce:surname>Nagayama</ce:surname></author><author seq="3"><ce:initials>M.</ce:initials><ce:indexed-name>Hashiba M.</ce:indexed-name><ce:surname>Hashiba</ce:surname></author><author seq="4"><ce:initials>M.</ce:initials><ce:indexed-name>Fujiyoshi M.</ce:indexed-name><ce:surname>Fujiyoshi</ce:surname></author><author seq="5"><ce:initials>M.</ce:initials><ce:indexed-name>Hizue M.</ce:indexed-name><ce:surname>Hizue</ce:surname></author><author seq="6"><ce:initials>H.</ce:initials><ce:indexed-name>Kodaira H.</ce:indexed-name><ce:surname>Kodaira</ce:surname></author><author seq="7"><ce:initials>M.</ce:initials><ce:indexed-name>Nishida M.</ce:indexed-name><ce:surname>Nishida</ce:surname></author><author seq="8"><ce:initials>K.</ce:initials><ce:indexed-name>Suzuki K.</ce:indexed-name><ce:surname>Suzuki</ce:surname></author><author seq="9"><ce:initials>Y.</ce:initials><ce:indexed-name>Takashima Y.</ce:indexed-name><ce:surname>Takashima</ce:surname></author><author seq="10"><ce:initials>Y.</ce:initials><ce:indexed-name>Ogino Y.</ce:indexed-name><ce:surname>Ogino</ce:surname></author><author seq="11"><ce:initials>D.</ce:initials><ce:indexed-name>Yasugi D.</ce:indexed-name><ce:surname>Yasugi</ce:surname></author><author seq="12"><ce:initials>Y.</ce:initials><ce:indexed-name>Yoneta Y.</ce:indexed-name><ce:surname>Yoneta</ce:surname></author><author seq="13"><ce:initials>S.</ce:initials><ce:indexed-name>Hisada S.</ce:indexed-name><ce:surname>Hisada</ce:surname></author><author seq="14"><ce:initials>T.</ce:initials><ce:indexed-name>Ohkura T.</ce:indexed-name><ce:surname>Ohkura</ce:surname></author><author seq="15"><ce:initials>K.</ce:initials><ce:indexed-name>Nakamura K.</ce:indexed-name><ce:surname>Nakamura</ce:surname></author></ref-authors><ref-sourcetitle>J. Toxicol. Sci.</ref-sourcetitle><ref-publicationyear first="2013"/><ref-volisspag><voliss volume="38"/><pagerange first="581" last="598"/></ref-volisspag></ref-info><ref-fulltext>Tamaki, C., Nagayama, T., Hashiba, M., Fujiyoshi, M., Hizue, M., Kodaira, H., Nishida, M., Suzuki, K., Takashima, Y., Ogino, Y., Yasugi, D., Yoneta, Y., Hisada, S., Ohkura, T., Nakamura, K., Potentials and limitations of nonclinical safety assessment for predicting clinical adverse drug reactions: correlation analysis of 142 approved drugs in Japan. J. Toxicol. Sci. 38 (2013), 581–598.</ref-fulltext></reference><reference id="26"><ref-info><ref-title><ref-titletext>Pharmacology Review 125294/S-000 Part 03 Neutroval</ref-titletext></ref-title><refd-itemidlist><itemid idtype="FRAGMENTID">bib26</itemid><itemid idtype="SGR">85046805515</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:indexed-name>Teva Pharmaceuticals</ce:indexed-name><ce:surname>Teva Pharmaceuticals</ce:surname></author></ref-authors><ref-publicationyear first="2010"/></ref-info><ref-fulltext>Teva Pharmaceuticals, Pharmacology Review 125294/S-000 Part 03 Neutroval. 2010.</ref-fulltext></reference><reference id="27"><ref-info><ref-title><ref-titletext>Evaluation of drug-induced QT interval prolongation in animal and human studies: a literature review of concordance</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.1111/bph.13207</itemid><itemid idtype="FRAGMENTID">bib27</itemid><itemid idtype="SGR">84937514953</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>H.M.</ce:initials><ce:indexed-name>Vargas H.M.</ce:indexed-name><ce:surname>Vargas</ce:surname></author><author seq="2"><ce:initials>A.S.</ce:initials><ce:indexed-name>Bass A.S.</ce:indexed-name><ce:surname>Bass</ce:surname></author><author seq="3"><ce:initials>J.</ce:initials><ce:indexed-name>Koerner J.</ce:indexed-name><ce:surname>Koerner</ce:surname></author><author seq="4"><ce:initials>S.</ce:initials><ce:indexed-name>Matis-Mitchell S.</ce:indexed-name><ce:surname>Matis-Mitchell</ce:surname></author><author seq="5"><ce:initials>M.K.</ce:initials><ce:indexed-name>Pugsley M.K.</ce:indexed-name><ce:surname>Pugsley</ce:surname></author><author seq="6"><ce:initials>M.</ce:initials><ce:indexed-name>Skinner M.</ce:indexed-name><ce:surname>Skinner</ce:surname></author><author seq="7"><ce:initials>M.</ce:initials><ce:indexed-name>Burnham M.</ce:indexed-name><ce:surname>Burnham</ce:surname></author><author seq="8"><ce:initials>M.</ce:initials><ce:indexed-name>Bridgland-Taylor M.</ce:indexed-name><ce:surname>Bridgland-Taylor</ce:surname></author><author seq="9"><ce:initials>S.</ce:initials><ce:indexed-name>Pettit S.</ce:indexed-name><ce:surname>Pettit</ce:surname></author><author seq="10"><ce:initials>J.-P.</ce:initials><ce:indexed-name>Valentin J.-P.</ce:indexed-name><ce:surname>Valentin</ce:surname></author></ref-authors><ref-sourcetitle>Br. J. Pharmacol.</ref-sourcetitle><ref-publicationyear first="2015"/><ref-volisspag><voliss volume="172"/><pagerange first="4002" last="4011"/></ref-volisspag></ref-info><ref-fulltext>Vargas, H.M., Bass, A.S., Koerner, J., Matis-Mitchell, S., Pugsley, M.K., Skinner, M., Burnham, M., Bridgland-Taylor, M., Pettit, S., Valentin, J.-P., Evaluation of drug-induced QT interval prolongation in animal and human studies: a literature review of concordance. Br. J. Pharmacol. 172 (2015), 4002–4011, 10.1111/bph.13207.</ref-fulltext></reference><reference id="28"><ref-info><ref-title><ref-titletext>Are animal models as good as we think?</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.1016/j.theriogenology.2007.09.030</itemid><itemid idtype="FRAGMENTID">bib28</itemid><itemid idtype="SGR">36448954646</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>R.J.</ce:initials><ce:indexed-name>Wall R.J.</ce:indexed-name><ce:surname>Wall</ce:surname></author><author seq="2"><ce:initials>M.</ce:initials><ce:indexed-name>Shani M.</ce:indexed-name><ce:surname>Shani</ce:surname></author></ref-authors><ref-sourcetitle>Theriogenology</ref-sourcetitle><ref-publicationyear first="2008"/><ref-volisspag><voliss volume="69"/><pagerange first="2" last="9"/></ref-volisspag></ref-info><ref-fulltext>Wall, R.J., Shani, M., Are animal models as good as we think?. Theriogenology 69 (2008), 2–9, 10.1016/j.theriogenology.2007.09.030.</ref-fulltext></reference><reference id="29"><ref-info><ref-title><ref-titletext>An analysis of the attrition of drug candidates from four major pharmaceutical companies</ref-titletext></ref-title><refd-itemidlist><itemid idtype="FRAGMENTID">bib29</itemid><itemid idtype="SGR">84934439985</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>M.J.</ce:initials><ce:indexed-name>Waring M.J.</ce:indexed-name><ce:surname>Waring</ce:surname></author><author seq="2"><ce:initials>J.</ce:initials><ce:indexed-name>Arrowsmith J.</ce:indexed-name><ce:surname>Arrowsmith</ce:surname></author><author seq="3"><ce:initials>A.R.</ce:initials><ce:indexed-name>Leach A.R.</ce:indexed-name><ce:surname>Leach</ce:surname></author><author seq="4"><ce:initials>P.D.</ce:initials><ce:indexed-name>Leeson P.D.</ce:indexed-name><ce:surname>Leeson</ce:surname></author><author seq="5"><ce:initials>S.</ce:initials><ce:indexed-name>Mandrell S.</ce:indexed-name><ce:surname>Mandrell</ce:surname></author><author seq="6"><ce:initials>R.M.</ce:initials><ce:indexed-name>Owen R.M.</ce:indexed-name><ce:surname>Owen</ce:surname></author><author seq="7"><ce:initials>G.</ce:initials><ce:indexed-name>Pairaudeau G.</ce:indexed-name><ce:surname>Pairaudeau</ce:surname></author><author seq="8"><ce:initials>W.D.</ce:initials><ce:indexed-name>Pennie W.D.</ce:indexed-name><ce:surname>Pennie</ce:surname></author><author seq="9"><ce:initials>S.D.</ce:initials><ce:indexed-name>Pickett S.D.</ce:indexed-name><ce:surname>Pickett</ce:surname></author><author seq="10"><ce:initials>J.</ce:initials><ce:indexed-name>Wang J.</ce:indexed-name><ce:surname>Wang</ce:surname></author><author seq="11"><ce:initials>O.</ce:initials><ce:indexed-name>Wallace O.</ce:indexed-name><ce:surname>Wallace</ce:surname></author><author seq="12"><ce:initials>A.</ce:initials><ce:indexed-name>Weir A.</ce:indexed-name><ce:surname>Weir</ce:surname></author></ref-authors><ref-sourcetitle>Nat. Rev. Drug Discov.</ref-sourcetitle><ref-publicationyear first="2015"/><ref-volisspag><voliss volume="14"/><pagerange first="475" last="486"/></ref-volisspag></ref-info><ref-fulltext>Waring, M.J., Arrowsmith, J., Leach, A.R., Leeson, P.D., Mandrell, S., Owen, R.M., Pairaudeau, G., Pennie, W.D., Pickett, S.D., Wang, J., Wallace, O., Weir, A., An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat. Rev. Drug Discov. 14 (2015), 475–486.</ref-fulltext></reference><reference id="30"><ref-info><ref-title><ref-titletext>DrugBank 5.0: a major update to the DrugBank database for 2018</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.1093/nar/gkx1037</itemid><itemid idtype="FRAGMENTID">bib30</itemid><itemid idtype="SGR">85040924244</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>D.S.</ce:initials><ce:indexed-name>Wishart D.S.</ce:indexed-name><ce:surname>Wishart</ce:surname></author><author seq="2"><ce:initials>Y.D.</ce:initials><ce:indexed-name>Feunang Y.D.</ce:indexed-name><ce:surname>Feunang</ce:surname></author><author seq="3"><ce:initials>A.C.</ce:initials><ce:indexed-name>Guo A.C.</ce:indexed-name><ce:surname>Guo</ce:surname></author><author seq="4"><ce:initials>E.J.</ce:initials><ce:indexed-name>Lo E.J.</ce:indexed-name><ce:surname>Lo</ce:surname></author><author seq="5"><ce:initials>A.</ce:initials><ce:indexed-name>Marcu A.</ce:indexed-name><ce:surname>Marcu</ce:surname></author><author seq="6"><ce:initials>J.R.</ce:initials><ce:indexed-name>Grant J.R.</ce:indexed-name><ce:surname>Grant</ce:surname></author><author seq="7"><ce:initials>T.</ce:initials><ce:indexed-name>Sajed T.</ce:indexed-name><ce:surname>Sajed</ce:surname></author><author seq="8"><ce:initials>D.</ce:initials><ce:indexed-name>Johnson D.</ce:indexed-name><ce:surname>Johnson</ce:surname></author><author seq="9"><ce:initials>C.</ce:initials><ce:indexed-name>Li C.</ce:indexed-name><ce:surname>Li</ce:surname></author><author seq="10"><ce:initials>Z.</ce:initials><ce:indexed-name>Sayeeda Z.</ce:indexed-name><ce:surname>Sayeeda</ce:surname></author><author seq="11"><ce:initials>N.</ce:initials><ce:indexed-name>Assempour N.</ce:indexed-name><ce:surname>Assempour</ce:surname></author><author seq="12"><ce:initials>I.</ce:initials><ce:indexed-name>Iynkkaran I.</ce:indexed-name><ce:surname>Iynkkaran</ce:surname></author><author seq="13"><ce:initials>Y.</ce:initials><ce:indexed-name>Liu Y.</ce:indexed-name><ce:surname>Liu</ce:surname></author><author seq="14"><ce:initials>A.</ce:initials><ce:indexed-name>Maciejewski A.</ce:indexed-name><ce:surname>Maciejewski</ce:surname></author><author seq="15"><ce:initials>N.</ce:initials><ce:indexed-name>Gale N.</ce:indexed-name><ce:surname>Gale</ce:surname></author><author seq="16"><ce:initials>A.</ce:initials><ce:indexed-name>Wilson A.</ce:indexed-name><ce:surname>Wilson</ce:surname></author><author seq="17"><ce:initials>L.</ce:initials><ce:indexed-name>Chin L.</ce:indexed-name><ce:surname>Chin</ce:surname></author><author seq="18"><ce:initials>R.</ce:initials><ce:indexed-name>Cummings R.</ce:indexed-name><ce:surname>Cummings</ce:surname></author><author seq="19"><ce:initials>D.</ce:initials><ce:indexed-name>Le D.</ce:indexed-name><ce:surname>Le</ce:surname></author><author seq="20"><ce:initials>A.</ce:initials><ce:indexed-name>Pon A.</ce:indexed-name><ce:surname>Pon</ce:surname></author><author seq="21"><ce:initials>C.</ce:initials><ce:indexed-name>Knox C.</ce:indexed-name><ce:surname>Knox</ce:surname></author><author seq="22"><ce:initials>M.</ce:initials><ce:indexed-name>Wilson M.</ce:indexed-name><ce:surname>Wilson</ce:surname></author></ref-authors><ref-sourcetitle>Nucleic Acids Res.</ref-sourcetitle><ref-publicationyear first="2017"/></ref-info><ref-fulltext>Wishart, D.S., Feunang, Y.D., Guo, A.C., Lo, E.J., Marcu, A., Grant, J.R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., Assempour, N., Iynkkaran, I., Liu, Y., Maciejewski, A., Gale, N., Wilson, A., Chin, L., Cummings, R., Le, D., Pon, A., Knox, C., Wilson, M., DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res., 2017, 10.1093/nar/gkx1037.</ref-fulltext></reference><reference id="31"><ref-info><ref-title><ref-titletext>Contingency table involving small numbers and the χ2 test</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.2307/2983604</itemid><itemid idtype="FRAGMENTID">bib31</itemid><itemid idtype="SGR">0000993098</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>F.</ce:initials><ce:indexed-name>Yates F.</ce:indexed-name><ce:surname>Yates</ce:surname></author></ref-authors><ref-sourcetitle>Suppl. to J. R. Stat. Soc.</ref-sourcetitle><ref-publicationyear first="1934"/><ref-volisspag><voliss volume="2"/><pagerange first="217" last="235"/></ref-volisspag></ref-info><ref-fulltext>Yates, F., Contingency table involving small numbers and the χ2 test. Suppl. to J. R. Stat. Soc. 2 (1934), 217–235, 10.2307/2983604.</ref-fulltext></reference></bibliography></tail></bibrecord></item></abstracts-retrieval-response>